Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending December 2014, with the report dated December 1, 2014. The filing serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a capital structure notification and does not contain financial performance data.
Material Changes
The filing details the Company's issued share capital as of November 30, 2014:
- Total Issued Ordinary Shares: 5,354,848,976 (25p each).
- Treasury Shares: 491,515,950.
- Total Voting Rights: 4,863,333,026.
No comparative data for prior periods is included in this specific filing to determine material changes in share count.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary, risks, contingencies, or unusual items. The document's sole purpose is to inform shareholders of the denominator to be used for calculating notification thresholds under the Financial Conduct Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of voting rights (4,863,333,026) against the latest annual report (Form 20-F) to ensure consistency.
- Confirm the number of treasury shares held (491,515,950) to calculate the correct denominator for ownership threshold notifications.
- Check subsequent filings for any changes in share capital or treasury holdings after November 30, 2014.